A. Di Cesare, “Therapeutic Modulation Of Peripheral Blood Cells And Inflammatory Indices During 52 Weeks Of Risankizumab In Responder Patients With Moderate-to-Severe Psoriasis: Results From A Multicenter Prospective Study”, Dermatol Pract Concept, vol. 15, no. 4, p. 5733, Oct. 2025, doi: 10.5826/dpc.1504a5733.